Stockreport

Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer [Yahoo! Finance]

Palvella Therapeutics, Inc.  (PVLA) 
PDF the company reported the Phase 2 TOIVA readout for Qtorin rapamycin in cutaneous venous malformations. The firm says 10 of 15 patients presented as “much improved” or “v [Read more]